Journal of pharmacy practice最新文献_第3页

Oral Fluconazole Absorption in a Complicated Post-Roux-en-Y Gastric Bypass Patient: A Case Report. roux -en- y胃旁路术后复杂患者口服氟康唑吸收1例报告

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-03-20 DOI: 10.1177/08971900251328787

Diana R Langworthy, Jennifer K Ross

{"title":"Oral Fluconazole Absorption in a Complicated Post-Roux-en-Y Gastric Bypass Patient: A Case Report.","authors":"Diana R Langworthy, Jennifer K Ross","doi":"10.1177/08971900251328787","DOIUrl":"10.1177/08971900251328787","url":null,"abstract":"Introduction: Roux-en-Y gastric bypass (RYGB) is a surgical weight-loss procedure that combines gastric restriction with malabsorption for weight reduction. There is currently a paucity of data to guide pharmacists and healthcare providers in optimizing oral medication therapy in patients with a history of bariatric surgery. Fluconazole is a commonly used triazole antifungal with high oral bioavailability. The literature is limited regarding how RYGB affects oral fluconazole absorption. Case: We investigated fluconazole oral bioavailability in a patient with a history of RYGB status-post revision with esophagojejunal anastomosis. The patient had been maintained on combination therapy with intravenous (IV) micafungin and oral fluconazole due to persistent candidemia prior to source control and concerns regarding fluconazole absorption. On admission, the patient was switched to IV fluconazole in the setting of possible small bowel obstruction. Steady-state fluconazole trough levels obtained during IV and oral therapy were 41.9 μg/mL and 44.4 μg/mL, respectively. Conclusion: We were able to demonstrate oral fluconazole maintains high bioavailability in a patient with RYGB. Fluconazole displays linear pharmacokinetics, therefore the degree of oral absorption reduction would directly correspond to a decreased trough level. Pharmacists and providers should continue to be vigilant when evaluating drug efficacy in patients who have undergone gastric bypass procedures, especially those with malabsorptive mechanisms.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"113-116"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lurasidone-Induced Tardive Dyskinesia Reversed With Lithium Therapy: A Case Report. 锂离子治疗逆转鲁拉西酮诱导的迟发性运动障碍1例。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-03-14 DOI: 10.1177/08971900251326824

Alice Gelman, Tamar Jacobsohn, Hyogun Yi, Aaron Pinkhasov

{"title":"Lurasidone-Induced Tardive Dyskinesia Reversed With Lithium Therapy: A Case Report.","authors":"Alice Gelman, Tamar Jacobsohn, Hyogun Yi, Aaron Pinkhasov","doi":"10.1177/08971900251326824","DOIUrl":"10.1177/08971900251326824","url":null,"abstract":"Tardive dyskinesia (TD) is a syndrome that causes chronic, involuntary, and disruptive movements of the body and/or face that is a severe, potentially irreversible adverse effect of long-term antipsychotic use. It has wide-reaching effects on patients' well-being, quality of life,1 and treatment adherence.2 Thus, TD is debilitating, leading to social withdrawal,3 and workplace absenteeism.1 Current data on tardive dyskinesia treatment are limited, and prevention, primarily through the modification of antipsychotic regimens, remains the most effective strategy.4 Recent systematic review has shown valbenazine and vitamin E are the only treatments significantly more effective compared to placebo in treatment of TD, although valbenazine is associated with significant side effects.5 We present a case of a 76-year-old female with a diagnosis of Bipolar II Disorder (BD) who developed TD after treatment with lurasidone for 10 years. After struggling with both her BD and TD symptoms for 3 years, she sought care at our clinic where we prescribed 300 mg daily of lithium. At her follow-up visit 5 weeks later, her TD symptoms were greatly improved, with sustained benefits observed at following visits. This article reviews the literature discussing the interplay between lithium and TD and presents a case report of TD improvement after lithium augmentation for treatment-resistant depression. While this case suggests a potential role in TD treatment, the role of lithium in TD treatment remains controversial.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"109-112"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Prospective Audit and Feedback by Transitions of Care Pharmacists on the Management of Community-Acquired Pneumonia. 前瞻审核及转岗药师反馈对社区获得性肺炎管理的影响。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-05-31 DOI: 10.1177/08971900251345976

Isabella N Hernandez, Anastasia Bilinskaya, Shally S Singh, David M O'Sullivan, Abigail M Henry

{"title":"Impact of Prospective Audit and Feedback by Transitions of Care Pharmacists on the Management of Community-Acquired Pneumonia.","authors":"Isabella N Hernandez, Anastasia Bilinskaya, Shally S Singh, David M O'Sullivan, Abigail M Henry","doi":"10.1177/08971900251345976","DOIUrl":"10.1177/08971900251345976","url":null,"abstract":"Background: The 2019 Center for Disease Control and Prevention's Core Elements of Hospital Antibiotic Stewardship identifies community-acquired pneumonia (CAP) as a crucial area for improving antibiotic use. Transitions of care (TOC) pharmacists can optimize medication therapy for CAP patients. Methods: This was a retrospective, multi-hospital analysis of discharge antibiotic prescribing. Between December 1, 2022, and June 30, 2023, TOC pharmacists intervened to decrease discharge days of therapy (DOT) for CAP therapy. The study compared records of CAP patients with a TOC antibiotic stewardship intervention vs those without. An additional three-group analysis compared patients without an intervention to those with an accepted intervention to those with a rejected intervention. Results: 196 patient records were included in the analysis; 80 had a TOC pharmacist intervention and 116 did not. 62 interventions were accepted and 18 were rejected. Mean final discharge DOT was 3.8 ± 1.7 days in the non-intervention group and 3.4 ± 1.6 days in the intervention group (P = 0.231). Mean total DOT was 6.8 ± 2.3 days and 6.8 ± 1.8 days, respectively (P = 0.963). The percentage of patients with appropriate total DOT was 59.5% and 66.3%, respectively (P = 0.337). In the three-group analysis, mean final discharge DOT was 2.9 ± 1.7 days in the accepted group and 4.2 ± 0.9 days in the rejected group (P = 0.030). Mean total DOT was 6.4 ± 1.6 days and 8.1 ± 1.8 days, respectively (P = 0.009). The percentage of patients with appropriate total DOT was 82.3% and 11.1%, respectively (P < 0.001). Conclusion: The accepted TOC pharmacist interventions significantly reduced both discharge DOT and total DOT. These findings emphasize the impact TOC pharmacists can have with antimicrobial stewardship initiatives.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"85-92"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Two Empiric Extended-Infusion Dosing Approaches for Piperacillin-Tazobactam in Critically Ill Patients: 3.375 grams Versus 4.5 grams. 危重患者哌拉西林-他唑巴坦两种经验性延长输液给药方式的比较：3.375 g vs 4.5 g。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-08-02 DOI: 10.1177/08971900251365827

Elizabeth A Feldman, Erica L Barbay, Robert W Seabury, Valerie M Amedeo, Wesley D Kufel

引用次数: 0

Delivering Diabetes Education and Enhanced Services Within a Clinically Integrated Community Pharmacy Network. 在临床整合的社区药房网络中提供糖尿病教育和增强服务。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-06-09 DOI: 10.1177/08971900251350509

Christopher J Daly, Merin V Panthapattu, Frances Murray, Ryan Lindenau, Amanda A Foster, David M Jacobs

{"title":"Delivering Diabetes Education and Enhanced Services Within a Clinically Integrated Community Pharmacy Network.","authors":"Christopher J Daly, Merin V Panthapattu, Frances Murray, Ryan Lindenau, Amanda A Foster, David M Jacobs","doi":"10.1177/08971900251350509","DOIUrl":"10.1177/08971900251350509","url":null,"abstract":"Introduction: With the increasing adoption of alternative payment models (APM) in the U.S. healthcare system there is a growing interest in measuring pharmacy performance with a focus on preventive care and chronic disease management. The Community Pharmacy Enhanced Services Network (CPESN) has been established throughout the U.S. to incorporate high-performing pharmacies to provide enhanced services for high-risk patients including those with diabetes. Methods: The primary objective of this study is to assess the readiness of community pharmacists within CPESN to deliver minimum enhanced services (MES) and diabetes self-management education and support (DSMES) among diabetes patients. A cross-sectional survey was distributed via email to all pharmacies within CPESN New York. Descriptive statistics were utilized to assess survey responses. Results: A total of 84 participants responded to the survey. Top DSMES services offered included: education on blood glucose monitoring (95%), education on lifestyle changes (88%), and monitoring medication adherence to diabetes-related medications (88%). The most time spent per week on DSMES services was for monitoring medication adherence to diabetes-related medications (5.9 +/- 7.0 hours). Top facilitators included technology to execute workflow (55%), adequate workflow design (54%), and proper training for pharmacy personnel (53%). Common barriers in executing services are lack of collaboration with other health professionals (54%) and proper training of pharmacy personnel (49%). Conclusion: CPESN-NY pharmacies demonstrate the opportunity to adapt clinical services including DSMES, which will enhance their performance measures in APMs. Facilitators and barriers have been identified thus next steps in the would be to address how to overcome these barriers.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"93-103"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Intravenous Push Levetiracetam in an Academic Children's Hospital. 某学院型儿童医院左乙拉西坦静脉推注的安全性

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-06-26 DOI: 10.1177/08971900251355333

Aneesha Santhosh, Daniel Abazia, Jessica Lise, Nadia Awad

{"title":"Safety of Intravenous Push Levetiracetam in an Academic Children's Hospital.","authors":"Aneesha Santhosh, Daniel Abazia, Jessica Lise, Nadia Awad","doi":"10.1177/08971900251355333","DOIUrl":"10.1177/08971900251355333","url":null,"abstract":"Background: Evidence supports the safe administration of levetiracetam as a rapid intravenous push (IVP) in patients experiencing breakthrough seizures or status epilepticus. Use of this route of administration may decrease morbidity and mortality by reducing time to medication delivery. Though this practice has become increasingly common in adults, the safety of IVP levetiracetam in pediatric patients is not well documented. Objective: To evaluate the safety of IVP levetiracetam in pediatric patients. Methods: Patients who received IV piggyback (IVPB) or IVP levetiracetam and were between the ages of 12 months and 18 years old were eligible for inclusion. Medication regimen data recorded includes the dose of levetiracetam, number of doses administered, and total days of administration. Additionally, time points related to order entry, pharmacist verification, and dose administration was recorded. Safety endpoints included rates of bradycardia, hypotension, behavioral changes, and cutaneous drug reactions. Descriptive and inferential statistical analysis was performed using SPSS software. Results: This study showed IVP levetiracetam has a similar rate of adverse effects when compared to IVPB levetiracetam in patients over the age of one (5.5% vs 7.5%, P = 0.3589). In addition, there was improvement in the time to administration of levetiracetam (50 min in the IVPB group and 23 min in the IVP group [P = .0008]). Conclusion: Pediatric patients who received undiluted (100 mg/mL) levetiracetam IVP over 5 min had a similar adverse event incidence when compared to those who received the anti-epileptic drug (AED) as an IVPB. This evaluation demonstrated that doses up to 1500 mg of undiluted IVP levetiracetam is safe for pediatric patients.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"104-108"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting Rhinitis Medicamentosa: Examining the Evidence on Topical Nasal Decongestants. 重访药物性鼻炎：检查局部减充血剂的证据。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2025-06-28 DOI: 10.1177/08971900251350510

Martina Hagen, Gabor Varbiro, Elisa Montanari, Mariane Ballerini Fernandes

{"title":"Revisiting Rhinitis Medicamentosa: Examining the Evidence on Topical Nasal Decongestants.","authors":"Martina Hagen, Gabor Varbiro, Elisa Montanari, Mariane Ballerini Fernandes","doi":"10.1177/08971900251350510","DOIUrl":"10.1177/08971900251350510","url":null,"abstract":"Background: Over-the-counter topical nasal decongestants are effective and well-tolerated treatments for the temporary relief of nasal congestion, a symptom that can impair quality of life. Their duration of use is limited owing to potential for rhinitis medicamentosa (RM) or rebound congestion (RC), despite uncertainties around the clinical occurrence or onset of these phenomena. Objective: To investigate the clinical occurrence and onset of RM, RC or tolerance with topical nasal decongestants to inform evidence-based recommendation practices for pharmacists and ensure patients do not forego potentially beneficial treatments. Methods: A literature search was conducted with ProQuest to identify and synthesize evidence on RM, RC or tolerance with nasal decongestant sprays or drops. A respiratory specialist and community pharmacist provided clinical perspectives. Results: Eighteen articles were assessed, reporting 13 studies with oxymetazoline, five studies with xylometazoline. There was no evidence of RM or RC after 7 days with oxymetazoline (up to 400 μg total daily dose) or up to 10-days with xylometazoline (840 μg total daily dose). Well-designed studies suggested no occurrence of RM, RC or tolerance with up to 4 weeks of oxymetazoline. No studies evaluating naphazoline, phenylephrine or ephedrine were identified. Conclusion: Oxymetazoline and xylometazoline are highly effective at rapidly improving nasal congestion and have well-established safety profiles. Well-designed studies yielded no evidence of RM, RC or tolerance when used short-term at commonly recommended dosing and frequency. Since some patients may exceed the duration of use in the label, pharmacists can play a vital role in counseling patients on proper intranasal decongestant use and treatment duration.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"117-139"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Community Pharmacists Identification of Gaps in Care - Statin Utilization for Primary Prevention. 社区药剂师对护理差距的识别--使用他汀类药物进行初级预防。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-04-01 Epub Date: 2024-06-24 DOI: 10.1177/08971900241262362

Raechel T White, Kjersten Sankey, Joe R Anderson, Alexander J Bos, Kelsea Gallegos Aragon, Diana D Martinez-Nava, Annajita M Rubio, Robyn M Turner, Gretchen M Ray

{"title":"Community Pharmacists Identification of Gaps in Care - Statin Utilization for Primary Prevention.","authors":"Raechel T White, Kjersten Sankey, Joe R Anderson, Alexander J Bos, Kelsea Gallegos Aragon, Diana D Martinez-Nava, Annajita M Rubio, Robyn M Turner, Gretchen M Ray","doi":"10.1177/08971900241262362","DOIUrl":"10.1177/08971900241262362","url":null,"abstract":"Background: Statins are a highly effective lipid-lowering therapy associated with significant reductions in atherosclerotic cardiovascular disease (ASCVD) events and death. Despite these benefits, statins are underutilized. Pharmacist-led interventions to increase statin prescribing are effective. To our knowledge, no prior studies implemented a comprehensive cardiovascular risk assessment utilizing point-of-care (POC) testing in community pharmacies. Objectives: The primary objective was to determine if community pharmacists can be utilized to identify gaps in care regarding appropriate use of statin therapy for prevention of ASCVD events in HPSAs. Secondary objectives were to assess public interest in ASCVD risk assessment and statin prescribing by the pharmacist, and to identify factors associated with statin gaps in care. Methods: A cross-sectional study was conducted at three independent community pharmacies. Participants were identified based on age and medication history and were scheduled at their pharmacy to receive a comprehensive ASCVD risk screening consisting of POC measurement of a complete lipid panel, blood glucose or A1C, and blood pressure. Participants were informed of their statin candidacy at the screening. Participants completed a survey regarding perceptions of the services provided and opinions of statin prescribing by pharmacists. Results: Of the 57 participants, 43 (75.4%) were possible statin candidates. Most indicated trusting their pharmacist to prescribe a cholesterol-lowering medication and felt insurance should pay for these screenings. Conclusion: ASCVD risk assessment conducted within the community pharmacy setting can be utilized to identify treatment gaps in statin use. Participants indicated trusting pharmacists to provide this service and found the service valuable.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"76-84"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjunctive Muscle Relaxants and Opioid Use Following Total Knee Arthroplasty. 全膝关节置换术后辅助肌肉松弛剂和阿片类药物的使用。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-03-30 DOI: 10.1177/08971900261439195

Carlina J Grindeland, Colin P Murphy, Jeremy W Grindeland, Hallie Thompson, Devendranath Mannuru

{"title":"Adjunctive Muscle Relaxants and Opioid Use Following Total Knee Arthroplasty.","authors":"Carlina J Grindeland, Colin P Murphy, Jeremy W Grindeland, Hallie Thompson, Devendranath Mannuru","doi":"10.1177/08971900261439195","DOIUrl":"https://doi.org/10.1177/08971900261439195","url":null,"abstract":"The opioid-abuse crisis in the United States is an area of concern within orthopedic practices. Postoperative pain following total knee arthroplasty (TKA) is one of the most common scenarios for opioid prescribing by orthopedic surgeons. Our study explores whether skeletal muscle relaxants (SMRs) may have utility as adjunct treatments to decrease opioid use postoperatively. A retrospective cohort study of patients that underwent elective TKA from July 2012 to July 2020 was performed. Patients prescribed scheduled SMRs while hospitalized were matched in a 1:2 fashion with control patients who were not prescribed SMRs. The primary outcome was Morphine Milligram Equivalents (MME) administered per day postoperatively. Secondary outcomes included pain score, length of stay, and postoperative complications. In total, 157 patients were included: 55 in the muscle relaxant group, and 102 in the control group. Median MMEs administered per day were similar between the two groups (80.2 vs 78.2, p = 0.37). There were no significant differences in adverse events between the two groups. Utilization of SMRs did not significantly decrease opioid use in the immediate postoperative period following TKA in this retrospective cohort. Patients that did receive SMRs did have higher POD1 pain scores and length of admission. All safety outcomes were similar between the groups. Further prospective studies are warranted to appropriately assess the potential of adjunct SMRs use to decrease opioid usage following TKA.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261439195"},"PeriodicalIF":1.1,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychotropics in Medication-Induced Priapism: A Case Series and Narrative Literature Review. 药物性阴茎勃起障碍的精神药物：一个病例系列和叙述性文献综述。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-03-28 DOI: 10.1177/08971900261439660

Tam Dong, Archana Jhawar, Zane Elfessi

{"title":"Psychotropics in Medication-Induced Priapism: A Case Series and Narrative Literature Review.","authors":"Tam Dong, Archana Jhawar, Zane Elfessi","doi":"10.1177/08971900261439660","DOIUrl":"https://doi.org/10.1177/08971900261439660","url":null,"abstract":"Priapism is a urologic emergency involving a sustained and painful penile erection resulting in tissue hypoxia and ischemia. This requires emergent intervention to preserve penile function and avoid complications including fibrosis and permanent erectile dysfunction. Ischemic priapism, or low-flow priapism, accounts for most cases and can be caused by numerous factors including pharmaceuticals. Typical antipsychotics are most often the causative agent, but antidepressants and other psychotropics similarly increase risk for ischemic priapism and must be acknowledged to prevent significant morbidity. This review (1) identifies common psychotropic medications associated with ischemic priapism through a narrative literature review and presentation of unique cases, (2) proposes the likely mechanisms of action for the implicated drug classes, and (3) outlines current evidence on the prevention and management of pharmacologically induced ischemic priapism. We conducted a narrative literature review of PubMed's database using MeSH Terms to identify relevant cases of priapism associated with psychotropic medications. 117 cases were identified, of which 85 had a clear association between medication usage and priapism. We also present 5 additional, unique cases of pharmacologically induced priapism involving less commonly implicated medications. Pharmacologically induced priapism is often a consequence of alpha-adrenergic antagonism which inhibits the sympathetic response necessary for penile detumescence and allows for a relative excess of parasympathetic response resulting in priapism. Treatment of ischemic priapism includes supportive measures, urology consultation for corporal irrigation and intracavernosal phenylephrine, or other surgical interventions. Medications implicated in causing ischemic priapism must be discontinued or at minimum dose reduced.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261439660"},"PeriodicalIF":1.1,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0